🎥 Out now: Part 1 of our 3-part 2025 Year in Review video Series In this session, I take stock of where the psychedelics field stands today across drug development, policy, and access programmes in this hour-long video, which focuses on 2025. psychedelicalpha.com/news/year-in...

Pα+ Psychedelic Bulletin #216: - Australia’s Psychedelics-for-Veterans Funding - New Mexico Targets 2026 Medical Psilocybin Launch - Otsuka’s “Novel Serotonergic Agonists” - Psilocybin Accelerates Brain Tumour Growth in Mice - TX $50M Ibogaine Study psychedelicalpha.com/news/p%ce%b1...

🐁 Very concerning finding: Psilocybin promotes brain tumour growth Authors caution against use of 5-HT2A agonists like psilocybin in patients with glioma, "given the profound and sustained tumor growth-promoting effects observed." Extends to other serotonergic drugs like LSD.

The Psychedelic Practitioner Issue 2: Preparation We explore the science and practice of psychedelic preparation through interviews, research reviews, and practitioner insights. Read now: psychedelicalpha.com/news/the-psy...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon I report from Washington, D.C., where conversations with regulators, lawmakers, and insiders suggest a turbulent but potentially transformative period ahead. psychedelicalpha.com/news/the-vie...

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition I spoke with the Compass exec at a pivotal time for the company, covering clinical infrastructure and credentialing through to comps and competition. psychedelicalpha.com/news/bringin...

BREAKING: ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics The U.S government agency revealed the project this evening. Read our breaking news story... psychedelicalpha.com/news/arpa-h-...

Psychedelic Bulletin 214: - Largest LSD Microdosing Trial Fails Across All Endpoints - AtaiBeckley’s Phase 2b Debrief - UK Gov. Holds Line on Psilocybin Despite MPs' Written Questions - MAHA Summit ft. Psychedelics - VA's Ph 3 Psilocybin Study - More... psychedelicalpha.com/news/p%ce%b1...

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action psychedelicalpha.com/news/beyond-...

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 We reviewed the readout and spoke with AtaiBeckley ( $ATAI ) CEO, Srinivas Rao, to dive deeper… psychedelicalpha.com/news/ataibec...

Psychedelic Bulletin 213 - Compass Accelerates Psilocybin Launch Plans by Almost a Year - Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans - AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidate psychedelicalpha.com/news/p%ce%b1...

BREAKING: Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months More detail, including interview with $CMPS CEO Kabir Nath, in our coverage... psychedelicalpha.com/news/compass...

Pα+ Psychedelic Bulletin 212 - Delix Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II - NRx Wants FDA to Ban Its Competitors’ Ketamine - Cybin Trades Toxic Financing for Top Tier Investors in $175M Raise psychedelicalpha.com/news/p%ce%b1...

Q3’25 Psychedelic Lobbying Update Here, we share our analysis of the latest developments in federal psychedelics lobbying for our Pα+ subscribers. Here’s a review of Q3 2025 activity… psychedelicalpha.com/news/q325-ps...

Pα+ Psychedelic Bulletin #211: - AbbVie Officially Enters Psychedelics - atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation - California Bill Signed - No Commissioner's National Priority Voucher for Psychedelics - and more... psychedelicalpha.com/news/p%ce%b1...

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda I speak with Schoevers, psychiatrist & epidemiologist who is, among other things, PI of PsyPal, a large, EU-funded study of psilocybin in patients w/ palliative care needs psychedelicalpha.com/news/a-europ...

Had a chat with @josh-hardman.bsky.social of @psychedelicalpha.bsky.social recently about recovered memories under #psychedelics. psychedelicalpha.com/news/recover...

Today, we launch The Psychedelic Practitioner by Psychedelic Alpha It’s designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. Read now: psychedelicalpha.com/news/the-psy...

Q3 2025 Psychedelic Investor Survey Results Today, we share topline results from the latest in our series of psychedelics investor surveys. Explore: psychedelicalpha.com/news/psyched...

The Psychedelic News Feed: Sept 29 - Oct 5, 2025 psychedelicalpha.com/news/the-psy...

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study We speak to researchers and take a deeper dive into the published study, with a focus on dose-response, safety, and MindMed's eschewing of psychotherapy. psychedelicalpha.com/news/breakth...

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence This morning, the UK's professional body for psychiatrists published a Position Statement and Guidance Booklet on the use of psychedelics. psychedelicalpha.com/news/uk-roya...

🎯 Our signature Bullseye chart has just been refreshed, mapping the global pipeline of psychedelic drug candidates, from discovery through to (potential) approval. Explore the latest Bullseye Charts + the full live Tracker now: psychedelicalpha.com/news/q325-ps...

From the EMA to Gustave Roussy, Dr. Florence Butlen-Ducuing has witnessed Europe’s psychedelic renaissance first-hand. I sat down with her to discuss. psychedelicalpha.com/news/no-prej...

On Thursday, we broke the news that FDA had published the Complete Response Letter (CRL) it sent to Lykos Therapeutics 13 months ago today, when it rejected its MDMA for PTSD new drug application. Today, we take a much closer (~5,000 word) look... More: psychedelicalpha.com/news/unpacki...

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) psychedelicalpha.com/news/breakin...

Pα+ Psychedelic Bulletin #207 - Lykos Rebrands to Resilient - Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision - AbbVie-Gilgamesh Deal Viewed as Validation - Psilocybin Rescheduling Petition Heads to HHS - Much, much more... psychedelicalpha.com/news/p%ce%b1...

Another scoop today. One of the world's best healthcare systems has decided to reimburse generic ketamine for treatment-resistant depression. Note that J&J's Spravato (esketamine nasal spray) is not reimbursed for TRD in the Nordic country. Big news... psychedelicalpha.com/news/norway-...

July 2025 Psychedelic Patent Update Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio. psychedelicalpha.com/news/july-20...

Discover Psychedelic Alpha like never before by using our new AI search tool, trained exclusively on in-house content and data. Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai

BREAKING: Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression Read our Deep Dive coverage, including a discussion with company management, now. psychedelicalpha.com/news/reunion...

Fantastic discussion between two excellent psychedelic scientists, spanning the generations of research progress! It really should say Huxley to Hefter to Jaster! Well done @jasteralaina.bsky.social!

I got to interview one of my academic heroes 😎🧠🍄 Read the interesting conversation on Psychedelic Alpha!

Heffter Research Institute co-founder Dr. Mark Geyer spoke with Dr. Alaina Jaster for our latest interview. Among the topics they discussed were so-called non-hallucinogenic psychedelics. Read more: psychedelicalpha.com/news/from-hu...

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research psychedelicalpha.com/news/from-hu...

Bulletin 206: - Q2’25 Psychedelic Lobbying Update - Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find - UK Moves Toward Easing Schedule I Research Restrictions But Keeps Industry at Arm’s Length - and more: psychedelicalpha.com/news/p%ce%b1...

At-Home Ketamine “Completely Irresponsible”, Says UK Expert “In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user. psychedelicalpha.com/news/therapy...

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches Charles Bliss speaks with Professor Celia Morgan about ketamine's promise and pitfalls. psychedelicalpha.com/news/therapy...

Last Week in Psychedelics. Bookmark the live Feed: psychedelicalpha.com/live

Pα+ Psychedelic Bulletin #205: - AbbVie Eyes Gilgamesh - Psychedelics Use Increases in U.S. - FDA Moves to Ban Kraton Compound 7-OH - What Is Sinema Selling? - and much, much more (5,000+ words!) psychedelicalpha.com/news/p%ce%b1...

Germany joins Switzerland in allowing certain European patients to access psilocybin when they have exhausted other options. The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy. More: psychedelicalpha.com/news/germany...

BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program. Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs. Details: psychedelicalpha.com/news/germany...

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2) Reporting by @jasteralaina.bsky.social. The entire Dispatch is now free to read. psychedelicalpha.com/news/dispatc...

Pα+ Psychedelic Bulletin #204 📍 FDA Keeps GH Research’s 5-MeO-DMT on Ice 📍 Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments 📍 HALT Fentanyl Act Could Streamline Schedule I Research 📍 and more... psychedelicalpha.com/news/p%ce%b1...

Q3 2025: Psychedelic Investor Survey If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey. docs.google.com/forms/d/1T_r...

Pα+ Psychedelic Bulletin #203: 🔑 Above the Paywall: Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression 🐁 Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution and more... psychedelicalpha.com/news/p%ce%b1...

Q2 2025 Psychedelic Funding Update Just over $150M flowed into psychedelic companies in Q2, all of which were drug developers. That's down around 60% from Q1. Explore the data and analysis: psychedelicalpha.com/news/psyched...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook I sat down with former U.S. Senator Kyrsten Sinema to discuss her advocacy for ibogaine. psychedelicalpha.com/news/from-se...

NEW: Oregon Psilocybin Services Tracker As the first cut of data from Oregon’s psilocybin program becomes available, we publish our first Oregon Psilocybin Services Tracker, which takes a deep dive into emerging trends through data visualisations & analysis. psychedelicalpha.com/news/oregon-...

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics Read our interview with Chris Timmermann: psychedelicalpha.com/news/reconst...